A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Conditions:   Pancreatic Adenocarcinoma;   Hepatocellular Carcinoma;   Squamous Cell Carcinoma;   Mesothelioma;   Non-squamous Non-small-cell Lung Cancer;   Triple Negative Breast Cancer;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Adenocarcinoma;   Gastric Adenocarcinoma Interventions:   Drug: TAK-500;   Drug: Pembrolizumab Sponsor:   Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 7, 2021 Category: Research Source Type: clinical trials

A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Condition:   Unresectable Mesothelioma Interventions:   Drug: Pembrolizumab;   Procedure: Image-guided cryoablation Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 7, 2021 Category: Research Source Type: clinical trials

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Conditions:   Pancreatic Adenocarcinoma;   Hepatocellular Carcinoma;   Squamous Cell Carcinoma;   Mesothelioma;   Non-squamous Non-small-cell Lung Cancer;   Triple Negative Breast Cancer;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Adenocarcinoma;   Gastric Adenocarcinoma Interventions:   Drug: TAK-500;   Drug: Pembrolizumab Sponsor:   Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 7, 2021 Category: Research Source Type: clinical trials

A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Condition:   Unresectable Mesothelioma Interventions:   Drug: Pembrolizumab;   Procedure: Image-guided cryoablation Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 7, 2021 Category: Research Source Type: clinical trials

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Conditions:   Pancreatic Adenocarcinoma;   Hepatocellular Carcinoma;   Squamous Cell Carcinoma;   Mesothelioma;   Non-squamous Non-small-cell Lung Cancer;   Triple Negative Breast Cancer;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Adenocarcinoma;   Gastric Adenocarcinoma Interventions:   Drug: TAK-500;   Drug: Pembrolizumab Sponsor:   Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 7, 2021 Category: Research Source Type: clinical trials